The Trump administration’s move to reclassify marijuana from Schedule I to Schedule III marks a major shift for the medical cannabis industry, with implications for taxation, research, insurance coverage, and patient access. While marijuana remains federally illegal unless Congress acts, the new classification recognizes accepted medical use and lowers regulatory barriers.